Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$806.06 USD

806.06
3,726,192

-0.08 (-0.01%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $804.12 -1.94 (-0.24%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - October 01, 2020

Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.

3 Reasons Growth Investors Will Love Lilly (LLY)

Lilly (LLY) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

Is Eli Lilly and (LLY) Stock Outpacing Its Medical Peers This Year?

Is (LLY) Outperforming Other Medical Stocks This Year?

Pfizer's (PFE) Xeljanz Gets FDA Approval for 4th Indication

Pfizer's (PFE) Xeljanz gets approval for children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA).

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

Eli Lilly (LLY) closed at $148.10 in the latest trading session, marking a -1.44% move from the prior day.

Gilead & Galapagos' RA Drug Receives Approval in Europe

Gilead (GILD) and partner Galapagos win approval for their rheumatoid arthritis (RA) drug in Europe.

Galapagos Gets First Commercial Drug With Jyseleca Approval

Galapagos (GLPG) and Gilead announce approval of Jyseleca in Europe as a treatment for rheumatoid arthritis patients.

Gilead's Rheumatoid Arthritis Drug Gets Approval in Japan

Gilead's (GILD) rheumatoid arthritis drug, Jyseleca, wins approval in Japan.

Sanghamitra Saha headshot

4 Reasons to Bet on Small-Cap ETFs Now

Small-cap stocks were hurt badly during the peak of the coronavirus-led lockdowns. Now, the gradual uptick of reopening trade has started to favor the small-cap spectrum.

Kinjel Shah headshot

Pharma Stock Roundup: J&J's Coronavirus Vaccine in Phase III, Other Updates

J&J (JNJ) becomes the fourth company to start a phase III study on its coronavirus vaccine candidate. CHMP recommends approval of several drugs.

RedHill Gets Nod in Brazil for Coronavirus Study on Opaganib

The Brazilian Health Regulatory Agency okays RedHill's (RDHL) to conduct a phase II/III study on opaganib for treating patients with severe COVID-19 infection and pneumonia. Stock up.

Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $151.18, marking a -1.94% move from the previous day.

Lilly's Olumiant Gets CHMP Nod for Eczema Label Expansion

Eli Lilly's (LLY) label expansion application for Olumiant to include atopic dermatitis in Europe patients gets CHMP recommendation for approval in Europe.

Sorrento Gets FDA Nod for Phase I Study on Coronavirus Antibody

Sorrento (SRNE) receives an FDA clearance to begin a phase I study on STI-1499 (COVI-GUARD) for treating hospitalized COVID-19 patients. Shares rise.

Lilly, Amgen Ink Manufacturing Deal for Coronavirus Antibodies

Eli Lilly (LLY) is developing several potential neutralizing antibodies to treat COVID-19.

Kinjel Shah headshot

Pharma Stock Roundup: AZN, LLY & PFE's Coronavirus Updates, MRK's New Cancer Deals

AstraZeneca (AZN) resumes its coronavirus vaccine study in the United Kingdom. Merck (MRK) inks two oncology deals with Seattle Genetics.

Roche's Actemra Meets Goal in Phase III Coronavirus Study

Roche's (RHHBY) phase III study, EMPACTA, evaluating Actemra in patients with COVID-19-associated pneumonia, meets primary endpoint.

Sanghamitra Saha headshot

No Rate Hike Until 2023: Here's How to Play With ETFs

As widely expected, the Fed held interest rates steady at a near-zero level in its latest meeting.

Lilly's Coronavirus Antibody Shows Positive Effect in Phase II

Lilly (LLY) is developing two coronavirus neutralizing antibody candidates as potential treatment for hospitalized COVID-19 patients. Treatment with one antibody candidate reduces hospitalization rate.

Lilly Drug Gets Fast Track to Improve Heart Attack Outcome

Lilly's (LLY) EMPACT-MI study is part of Jardiance's ENPOWER clinical program, which is studying the impact of Jardiance on major clinical cardiovascular and renal outcomes in a spectrum of cardio-renal-metabolic conditions.

OPKO Health Initiates Mid-Stage Study on Coronavirus Therapy

OPKO Health (OPK) is developing its marketed drug, Rayaldee, as a potential treatment for patients with mild-to-moderate COVID-19.

Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know

Eli Lilly (LLY) closed the most recent trading day at $150.08, moving +0.72% from the previous trading session.

Lilly's Olumiant Meets Primary Endpoint in Coronavirus Study

Eli Lilly (LLY) releases positive initial data from a phase III study evaluating Olumiant (baricitinib) in combination with Gilead's remdesivir for hospitalized patients with COVID-19.

Regeneron's Cocktail for Coronavirus Selected for RECOVERY Study

Regeneron's (REGN) investigational anti-viral antibody cocktail, REGN-COV2, has been selected for evaluation in the RECOVERY study.